S&P 500   3,974.32 (-0.08%)
DOW   32,513.21 (+0.25%)
QQQ   306.43 (-0.75%)
AAPL   156.94 (-0.85%)
MSFT   273.78 (-0.94%)
META   200.14 (-1.33%)
GOOGL   100.61 (-1.81%)
AMZN   97.72 (-0.33%)
TSLA   188.98 (-1.48%)
NVDA   262.74 (-0.97%)
NIO   9.16 (+2.58%)
BABA   96.02 (+11.50%)
AMD   93.83 (-2.88%)
T   18.92 (+0.26%)
F   11.58 (+0.52%)
MU   58.30 (-2.49%)
CGC   1.86 (-1.24%)
GE   92.96 (-0.38%)
DIS   95.55 (-0.07%)
AMC   4.64 (+1.98%)
PFE   40.19 (-0.07%)
PYPL   72.71 (-0.80%)
NFLX   328.32 (+0.20%)
S&P 500   3,974.32 (-0.08%)
DOW   32,513.21 (+0.25%)
QQQ   306.43 (-0.75%)
AAPL   156.94 (-0.85%)
MSFT   273.78 (-0.94%)
META   200.14 (-1.33%)
GOOGL   100.61 (-1.81%)
AMZN   97.72 (-0.33%)
TSLA   188.98 (-1.48%)
NVDA   262.74 (-0.97%)
NIO   9.16 (+2.58%)
BABA   96.02 (+11.50%)
AMD   93.83 (-2.88%)
T   18.92 (+0.26%)
F   11.58 (+0.52%)
MU   58.30 (-2.49%)
CGC   1.86 (-1.24%)
GE   92.96 (-0.38%)
DIS   95.55 (-0.07%)
AMC   4.64 (+1.98%)
PFE   40.19 (-0.07%)
PYPL   72.71 (-0.80%)
NFLX   328.32 (+0.20%)
S&P 500   3,974.32 (-0.08%)
DOW   32,513.21 (+0.25%)
QQQ   306.43 (-0.75%)
AAPL   156.94 (-0.85%)
MSFT   273.78 (-0.94%)
META   200.14 (-1.33%)
GOOGL   100.61 (-1.81%)
AMZN   97.72 (-0.33%)
TSLA   188.98 (-1.48%)
NVDA   262.74 (-0.97%)
NIO   9.16 (+2.58%)
BABA   96.02 (+11.50%)
AMD   93.83 (-2.88%)
T   18.92 (+0.26%)
F   11.58 (+0.52%)
MU   58.30 (-2.49%)
CGC   1.86 (-1.24%)
GE   92.96 (-0.38%)
DIS   95.55 (-0.07%)
AMC   4.64 (+1.98%)
PFE   40.19 (-0.07%)
PYPL   72.71 (-0.80%)
NFLX   328.32 (+0.20%)
S&P 500   3,974.32 (-0.08%)
DOW   32,513.21 (+0.25%)
QQQ   306.43 (-0.75%)
AAPL   156.94 (-0.85%)
MSFT   273.78 (-0.94%)
META   200.14 (-1.33%)
GOOGL   100.61 (-1.81%)
AMZN   97.72 (-0.33%)
TSLA   188.98 (-1.48%)
NVDA   262.74 (-0.97%)
NIO   9.16 (+2.58%)
BABA   96.02 (+11.50%)
AMD   93.83 (-2.88%)
T   18.92 (+0.26%)
F   11.58 (+0.52%)
MU   58.30 (-2.49%)
CGC   1.86 (-1.24%)
GE   92.96 (-0.38%)
DIS   95.55 (-0.07%)
AMC   4.64 (+1.98%)
PFE   40.19 (-0.07%)
PYPL   72.71 (-0.80%)
NFLX   328.32 (+0.20%)
NASDAQ:SPRB

Spruce Biosciences - SPRB Price Target & Analyst Ratings

$2.26
-0.05 (-2.16%)
(As of 03/28/2023 11:22 AM ET)
Add
Compare
Today's Range
$2.25
▼
$2.30
50-Day Range
$2.17
▼
$3.17
52-Week Range
$0.95
▼
$3.57
Volume
33,281 shs
Average Volume
1.63 million shs
Market Capitalization
$89.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.60

Spruce Biosciences Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 5 Analyst Ratings

Consensus Analyst Price Target

$7.60
236.28% Upside
High Prediction$10.00
Average Prediction$7.60
Low Prediction$4.00
TypeCurrent
3/28/22 to 3/28/23		1 Month Ago
2/26/22 to 2/26/23		3 Months Ago
12/28/21 to 12/28/22		1 Year Ago
3/28/21 to 3/28/22
Consensus Rating
Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
6 Buy rating(s)
Hold
0 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$7.60$8.83$9.00$9.43
Predicted Upside236.28% Upside417.58% Upside469.62% Upside277.47% Upside
Get Spruce Biosciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for SPRB and its competitors with MarketBeat's FREE daily newsletter.

SPRB Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

SPRB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Spruce Biosciences Stock vs. The Competition

TypeSpruce BiosciencesMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.64
2.47
Consensus RatingBuyBuyHold
Predicted Upside229.00% Upside2,000.97% Upside22.46% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/23/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy$20.00 ➝ $10.00+342.48%
3/17/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOutperform$4.00+72.41%
2/13/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOutperform$9.00 ➝ $8.00+203.03%
11/17/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOutperform$13.00 ➝ $8.00+572.26%
11/16/2022JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageMarket Outperform$8.00+661.90%
3/16/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating		J. Schwartz
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower TargetMarket Perform$5.00 ➝ $3.00+62.16%
3/8/2022LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$6.00+219.15%
12/10/2021Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageSpeculative Buy$7.00+173.44%
11/23/2021Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeOutperform ➝ Market Perform
(Data available from 3/28/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












SPRB Price Target - Frequently Asked Questions

What is Spruce Biosciences's consensus rating and price target?

According to the issued ratings of 5 analysts in the last year, the consensus rating for Spruce Biosciences stock is Buy based on the current 5 buy ratings for SPRB. The average twelve-month price prediction for Spruce Biosciences is $7.60 with a high price target of $10.00 and a low price target of $4.00. Learn more on SPRB's analyst rating history.

Do Wall Street analysts like Spruce Biosciences more than its competitors?

Analysts like Spruce Biosciences more than other Medical companies. The consensus rating score for Spruce Biosciences is 3.00 while the average consensus rating score for medical companies is 2.64. Learn more on how SPRB compares to other companies.

Does Spruce Biosciences's stock price have much upside?

According to analysts, Spruce Biosciences's stock has a predicted upside of 301.69% based on their 12-month price targets.

What analysts cover Spruce Biosciences?

Spruce Biosciences has been rated by Credit Suisse Group, HC Wainwright, and Royal Bank of Canada in the past 90 days.


Stock Ratings Reports and Tools

Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
Ratings for Popular Stocks:
This page (NASDAQ:SPRB) was last updated on 3/28/2023 by MarketBeat.com Staff